{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-016046","form_type":"8-K","ticker":"BIOA","cik":"0001709941","company_name":"BioAge Labs, Inc.","filed_at":"2026-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.965678+00:00","generated_at":"2026-05-16T09:34:08.772251+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioAge Labs expands BGE-102 into diabetic macular edema; Phase 1b/2a trial planned mid-2026","bullets":["Plans to initiate Phase 1b/2a proof-of-concept trial in DME in mid-2026; results expected mid-2027.","Preclinical DME model: oral BGE-102 achieved near-complete protection from vascular leakage and up to 90% preservation of microvascular integrity.","BGE-102 ongoing Phase 1 shows favorable tolerability and robust reductions in hsCRP, IL-6, and IL-1β.","Additional milestones: 1H2026 complete Phase 1, start CV risk Phase 2a; 2H2026 CV risk data.","Cites growing clinical evidence for targeting inflammation in retinal diseases, including intravitreal IL-6 inhibitors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-016046","json":"https://secwatch.observer/filing/0001193125-26-016046.json","markdown":"https://secwatch.observer/filing/0001193125-26-016046.md","text":"https://secwatch.observer/filing/0001193125-26-016046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526016046/0001193125-26-016046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526016046/bioa-20260120.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:34:08.772251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}